VIENNA – A certain amount of abstraction is hard to avoid at events like BIO Europe. At this week's meeting there's been no shortage of panels populated with old and wise big pharma executives and grizzled venture capital investors grandly pronouncing on the 'dos and don'ts' of partnering and deal-making. The onus, it seems, is always on the junior partner, which must learn to dance to the bigger partner's tune.